Ibrutinib (Imbruvica?) a small-drug inhibitor of Bruton tyrosine kinase (BTK) is currently undergoing clinical screening in patients with multiple myeloma (MM) yet important questions around the role of BTK in myeloma biology and treatment are outstanding. of key stemness genes (mRNA levels are elevated in myeloma cells compared to normal plasma cells. To complement these… Continue reading Ibrutinib (Imbruvica?) a small-drug inhibitor of Bruton tyrosine kinase (BTK) is